FDA has found that many clinical trials exclude people with psychiatric conditions, which is a problem given how many drugs exacerbate such conditions, Bob Temple, deputy center director for clinical science at FDA’s Center for Drug Evaluation and Research, said.
In the agency-sponsored study, “we generally found that people with co-morbidities were included,” Temple said at the recent annual meeting of the International Society for Pharmacoeconomics and Outcomes Research